SUTRO BIOPHARMA INC
For the period ended May 8, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 8, 2025 · Filed May 8, 2025
Use the contents to explore the available documents and sections.
STRO$9.62+4.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Corporate and Program Updates
Corporate and Program Updates
In March, Sutro announced completion of a strategic portfolio review resulting in the prioritization of its wholly-owned next-generation ADC programs. While Sutro will not continue the development of luveltamab tazevibulin (luvelta) on its own, it remains open to partnership opportunities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.